HBL HADASIT BIO HOLDINGS
Hadasit Bio-Holdings Ltd. ("HBL") was founded and floated on the Tel Aviv Stock Exchange (TASE : HDST ) and recently on the OTC (OTCBB : HADSY ) in order to allow public participation in the highly promising field of biotechnology. It serves as a precedent in biotech financing - for the first time, public investment is allowed to participate in a holding entity including companies based on IP generated by Israelโs foremost medical research center โ Hadassah University Hospital ("HU"). ... In addition to the public holdings (54%) โ including major Israeli institutional investors, HBL is held by Hadasit (www.hadasit.co.il) (36%) and Consensus Business Group (http://www.consensusbusiness.com) (10%). The traded stock, as a unique investment vehicle, provides investment exposure to a select cluster of 6 biotech companies - all based on inventions developed and owned by HU. HBL is a publicly traded subsidiary of Hadasit Ltd. โ the technology transfer company of the Hadassah University Hospital in Jerusalem, Israel. Hadasit was established for the purpose of promoting and commercializing the intellectual property (IP) and R&D capabilities generated by Hadassah, aimed at finding solutions to problems faced by modern medicine.
HBL HADASIT BIO HOLDINGS
Industry:
Biopharma Biotechnology Life Science
Founded:
2005-01-01
Status:
Active
Email Addresses:
[email protected]
Total Funding:
2 M USD
Technology used in webpage:
SPF Google Analytics Microsoft Exchange Online Office 365 Mail Google Maps Microsoft Azure DNS ASP.NET IIS Google Analytics Classic IIS 8
Similar Organizations
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Current Employees Featured
Founder
Stock Details
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2021-06-16 | KAHR medical | HBL Hadasit Bio Holdings investment in Venture Round - KAHR medical | 46.5 M USD |
2020-02-25 | KAHR medical | HBL Hadasit Bio Holdings investment in Venture Round - KAHR medical | 18 M USD |
2018-04-23 | Enlivex Therapeutics | HBL Hadasit Bio Holdings investment in Venture Round - Enlivex Therapeutics | 10 M USD |
2017-09-19 | Enlivex Therapeutics | HBL Hadasit Bio Holdings investment in Series B - Enlivex Therapeutics | 8 M USD |
2013-09-09 | KAHR medical | HBL Hadasit Bio Holdings investment in Venture Round - KAHR medical | 2.35 M USD |
2011-04-14 | KAHR medical | HBL Hadasit Bio Holdings investment in Venture Round - KAHR medical | 3 M USD |
2010-04-23 | ProtAb | HBL Hadasit Bio Holdings investment in Series A - ProtAb | 4 M USD |
2009-12-01 | KAHR medical | HBL Hadasit Bio Holdings investment in Venture Round - KAHR medical | 1.5 M USD |
2009-01-28 | KAHR medical | HBL Hadasit Bio Holdings investment in Venture Round - KAHR medical | 500 K USD |